Long-Term Outcomes with Lecanemab in Early Alzheimer&#39;s Disease: Initial Findings Through 60-Months of Clarity AD Open-Label Extension

Leqembi (lecanemab-irmb) - Biogen, Eisai

Christopher VAN DYCK1; David LI2; Michio KANEKIYO2; Shobha DHADDA2; Michelle GEE3; Steven HERSCH2; Michael IRIZARRY2; Lynn KRAMER2

Sep 26, 2026